Provided by Tiger Trade Technology Pte. Ltd.

Aligos Therapeutics, Inc.

12.11
-1.1900-8.95%
Volume:164.13K
Turnover:2.01M
Market Cap:74.49M
PE:-1.24
High:13.69
Open:13.43
Low:11.45
Close:13.30
52wk High:46.80
52wk Low:3.76
Shares:6.15M
Float Shares:3.00M
Volume Ratio:2.15
T/O Rate:5.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.7606
EPS(LYR):-20.9448
ROE:-141.82%
ROA:-54.70%
PB:1.04
PE(LYR):-0.58

Loading ...

Aligos Therapeutics Grants Stock Options to New Hires Under 2024 Inducement Plan

Reuters
·
Dec 12

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 12

Aligos Therapeutics Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B

Reuters
·
Dec 11

Aligos Therapeutics Showcases Positive Data at HEP-DART 2025 Meeting

Reuters
·
Dec 11

Piper Sandler Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)

TIPRANKS
·
Nov 25

Aligos Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Nov 14

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 14

Aligos Therapeutics Reports Positive 96-Week Data for Pevifoscorvir Sodium in Chronic Hepatitis B

Reuters
·
Nov 10

Aligos Therapeutics: Strategic Execution and Promising Pipeline Drive Buy Rating

TIPRANKS
·
Nov 10

Aligos Therapeutics Q3 EPS $(3.04) Misses $(2.27) Estimate, Sales $741.000K Beat $500.000K Estimate

Benzinga
·
Nov 06

Aligos Therapeutics Inc: Cash, Cash Equivalents and Investments Are Expected to Provide Sufficient Funding of Planned Operations Into Q3 of 2026

THOMSON REUTERS
·
Nov 06

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 06

Aligos Therapeutics Inc expected to post a loss of $1.90 a share - Earnings Preview

Reuters
·
Nov 04

Aligos Therapeutics to Present at Jefferies London Healthcare Conference

Reuters
·
Nov 04

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire
·
Oct 30

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 30

Aligos Therapeutics (ALGS) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Oct 28

Aligos Therapeutics’ Promising Hepatitis B Study: A Potential Game-Changer?

TIPRANKS
·
Oct 28

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

TIPRANKS
·
Oct 17

Aligos Therapeutics Receives Usan Council Approval for Pevifoscorvir Sodium as Nonproprietary Name for Alg-000184

THOMSON REUTERS
·
Oct 16